TAVI Wars, Episode III. Troubling data for the Acurate neo2 in the regulatory trial just presented here at #TCT2024 (currently unpublished), with increased cardiac mortality (as had occurred with the first-generation valve in our SCOPE 2 trial) and stroke, with noninferiority not achieved for the primary outcome compared with other commercially available valves. The discussion seems somewhat detached because if I had just entered the main arena now, I would have thought the trial was positive. They are justifying this with the high rate of underexpanded valves and are strongly recommending post-dilation after implantation, if necessary. What happens now?
SCAI Expert Consensus Statement on Management of In-Stent Restenosis and Stent Thrombosis - Journal of the Society for Cardiovascular Angiography & Interventions jscai.org/article/S2772-9303…